<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014156</url>
  </required_header>
  <id_info>
    <org_study_id>03.123</org_study_id>
    <nct_id>NCT01014156</nct_id>
  </id_info>
  <brief_title>Epoprostenol in Pulmonary Embolism</brief_title>
  <official_title>Effects of Intravenous Epoprostenol Sodium (Flolan®) in Patients With Moderate-to-Severe Pulmonary Thrombo-Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Free University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Free University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      You are admitted to hospital because of pulmonary embolism. You are treated with&#xD;
      anticoagulants.&#xD;
&#xD;
      The investigators know that, despite this treatment, pulmonary embolism can be a threat&#xD;
      especially if heart function is compromized.&#xD;
&#xD;
      The investigators investigate a well known study drug (epoprostenol) on top of regular&#xD;
      treatment with anticoagulants, to see if heart function can be optimized&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary thromboembolism (PE) with circulatory and/or respiratory symptoms is associated&#xD;
      with high morbidity and mortality. Acute pulmonary hypertension is the hallmark of severe PE,&#xD;
      and is to be held responsible for the full spectrum of clinical manifestations and&#xD;
      complications. Although it is common belief that only mechanical obstruction by thrombus mass&#xD;
      causes this pulmonary hypertension, there is strong evidence indicating that pulmonary&#xD;
      vasoconstriction contributes significantly to the rise in pulmonary vascular resistance.&#xD;
&#xD;
      Although all patients will receive anticoagulant treatment immediately after the diagnosis is&#xD;
      established, morbidity and mortality are still disturbingly high when circulatory and/or&#xD;
      respiratory symptoms accompany PE, or when hemodynamically stable PE patients have&#xD;
      echocardiographic signs of acute right ventricle overload. There are no generally accepted&#xD;
      guidelines for additional treatment options in these patients with moderate-to-severe PE.&#xD;
      Thrombolytic therapy is recommended by many when hemodynamic symptoms are severe, but its&#xD;
      effectiveness has never been proven in a controlled trial. In patients with moderate-to-large&#xD;
      PE associated with echocardiographic signs of right ventricle overload, but who are still&#xD;
      circulatory stable, mortality is increased, but thrombolytic therapy appears not to be&#xD;
      beneficial.&#xD;
&#xD;
      Given the plausible role of pulmonary vasoconstriction in the pathogenesis of PE associated&#xD;
      pulmonary hypertension, the potential benefit of pulmonary vasodilators is important.There is&#xD;
      experimental evidence that antagonising pulmonary vasoconstriction by the administration of&#xD;
      selective vasodilators may be beneficial in animals with PE. In addition, anecdotal evidence&#xD;
      of a similar kind exists for humans with acute PE.&#xD;
&#xD;
      We hypothesise that in PE patients who have echocardiographic evidence of acute right&#xD;
      ventricle overload, epoprostenol sodium (Flolan®) results in partial or complete reversal of&#xD;
      echocardiographic abnormalities, as well as in improvement in respiratory and circulatory&#xD;
      symptoms and signs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right ventricular end diastolic diameter (ultrasound)</measure>
    <time_frame>0, 2,5 4, 24 and 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>systolic pulmonary artery pressure (ultrasound)</measure>
    <time_frame>identical to primary measure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Acute Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>epoprostenol intraveneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>epoprostenol iv versus placebo iv, both on top of low molecular weight heparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoprostenol</intervention_name>
    <description>titration up to 4 ng/kg/min</description>
    <arm_group_label>epoprostenol intraveneously</arm_group_label>
    <other_name>prostacyclin, flolan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute (symptoms &lt;24 hrs) with right ventricular dilatation (&gt;30 mm end diastolic,&#xD;
             systolic PAP &gt; 50 mmHg,&#xD;
&#xD;
          -  absence of right ventricular wall hypertrophy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age below 18 years or above 70 years&#xD;
&#xD;
          -  body mass index &gt;35 kg/m2&#xD;
&#xD;
          -  duration of symptoms &gt;24 hours (since onset or acute increase in symptoms)&#xD;
&#xD;
          -  severe circulatory shock (systemic blood pressure systolic &lt;80 mmHg, or diastolic&#xD;
             blood pressure &lt;45 mmHg) or respiratory failure, requiring mechanical ventilation.&#xD;
&#xD;
          -  patients who, in the opinion of the supervising physician, require thrombolytic&#xD;
             therapy.&#xD;
&#xD;
          -  severe pre-existent cardiopulmonary disease (heart failure, obstructive pulmonary&#xD;
             disease, emphysema)&#xD;
&#xD;
          -  atrial fibrillation&#xD;
&#xD;
          -  refusal or inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Free University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>November 13, 2009</study_first_submitted>
  <study_first_submitted_qc>November 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2009</study_first_posted>
  <last_update_submitted>November 13, 2009</last_update_submitted>
  <last_update_submitted_qc>November 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Albertus Jozef Kooter</name_title>
    <organization>Free University Medical Center</organization>
  </responsible_party>
  <keyword>pulmonary embolism</keyword>
  <keyword>vasoconstriction</keyword>
  <keyword>right ventricular dysfunction</keyword>
  <keyword>epoprostenol</keyword>
  <keyword>acute pulmonary embolism with right ventricular dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoprostenol</mesh_term>
    <mesh_term>Tezosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

